A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2015
Price : $35 *
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 12 Feb 2015 Last checked against ClinicalTrials.gov record.
- 10 Feb 2015 Planned number of patients changed to 70.
- 09 Jan 2014 New trial record